ERBB2 and brain neoplasm: Yet, despite defining several potentially effective targets in adult brain tumors (e.g., IL13Rα2, HER2, and EGFRvIII), clinical testing of CAR T cells in brain tumors failed to produce complete and sustainable antitumor responses (5–8).